See more : Eventbrite, Inc. (EB) Income Statement Analysis – Financial Results
Complete financial analysis of Quest Diagnostics Incorporated (DGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quest Diagnostics Incorporated, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- XPO Logistics, Inc. (0M1O.L) Income Statement Analysis – Financial Results
- Orpea SA (ORP.PA) Income Statement Analysis – Financial Results
- Fulgent Sun International (Holding) Co., Ltd. (9802.TW) Income Statement Analysis – Financial Results
- Solera National Bancorp, Inc. (SLRK) Income Statement Analysis – Financial Results
- Damara Gold Corp. (DMR.V) Income Statement Analysis – Financial Results
Quest Diagnostics Incorporated (DGX)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.questdiagnostics.com
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.25B | 9.88B | 10.79B | 9.44B | 7.73B | 7.53B | 7.71B | 7.52B | 7.49B | 7.44B | 7.15B | 7.38B | 7.51B | 7.37B | 7.46B | 7.25B | 6.70B | 6.27B | 5.50B | 5.13B | 4.74B | 4.11B | 3.63B | 3.42B | 2.21B | 1.46B | 1.53B | 1.62B |
| Cost of Revenue | 6.29B | 6.45B | 6.58B | 5.80B | 5.04B | 4.93B | 4.72B | 4.62B | 4.66B | 4.64B | 4.33B | 4.36B | 4.40B | 4.32B | 4.32B | 4.26B | 3.97B | 3.70B | 3.26B | 2.99B | 2.77B | 2.43B | 2.15B | 1.97B | 1.32B | 813.90M | 875.50M | 1.01B |
| Gross Profit | 2.96B | 3.43B | 4.21B | 3.63B | 2.69B | 2.61B | 2.99B | 2.90B | 2.84B | 2.80B | 2.82B | 3.02B | 3.12B | 3.05B | 3.13B | 2.99B | 2.74B | 2.57B | 2.25B | 2.14B | 1.97B | 1.68B | 1.48B | 1.45B | 886.20M | 644.70M | 653.20M | 605.42M |
| Gross Profit Ratio | 32.00% | 34.74% | 39.02% | 38.50% | 34.80% | 34.59% | 38.79% | 38.58% | 37.85% | 37.63% | 39.46% | 40.88% | 41.48% | 41.41% | 42.03% | 41.29% | 40.79% | 41.04% | 40.82% | 41.66% | 41.57% | 40.79% | 40.69% | 42.49% | 40.19% | 44.20% | 42.73% | 37.46% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.00K | 27.00K | -18.00K | -34.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.62B | 1.87B | 1.73B | 1.55B | 1.46B | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Other Expenses | 0.00 | 131.00M | 101.00M | 112.00M | 1.00M | -8.00M | 16.00M | -48.00M | -143.00M | 4.00M | 8.00M | 6.70M | 305.79M | 48.47M | 27.04M | 33.98M | 30.87M | 10.91M | 20.49M | 6.70M | 8.20M | 8.37M | 46.11M | 134.30M | 90.80M | 68.80M | 76.40M | 711.38M |
| Operating Expenses | 1.76B | 2.01B | 1.83B | 1.66B | 1.46B | 1.50B | 1.83B | 1.74B | 1.77B | 1.82B | 1.82B | 1.82B | 2.12B | 1.76B | 1.77B | 1.77B | 1.64B | 1.44B | 1.28B | 1.23B | 1.17B | 1.08B | 1.06B | 1.14B | 734.20M | 550.40M | 578.50M | 1.21B |
| Cost & Expenses | 7.94B | 8.46B | 8.41B | 7.47B | 6.50B | 6.43B | 6.54B | 6.36B | 6.43B | 6.45B | 6.15B | 6.18B | 6.52B | 6.07B | 6.10B | 6.03B | 5.61B | 5.14B | 4.54B | 4.23B | 3.94B | 3.52B | 3.22B | 3.10B | 2.05B | 1.36B | 1.45B | 2.22B |
| Interest Income | 11.00M | 10.00M | 1.00M | 3.00M | 5.00M | 2.00M | 2.00M | 1.00M | 1.00M | 3.00M | 3.00M | 3.00M | 2.77M | 1.41M | 2.52M | 5.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 163.00M | 138.00M | 151.00M | 163.00M | 175.00M | 167.00M | 151.00M | 143.00M | 153.00M | 164.00M | 159.00M | 164.70M | 170.60M | 146.10M | 144.10M | 185.48M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 439.00M | 437.00M | 408.00M | 361.00M | 329.00M | 309.00M | 270.00M | 249.00M | 304.00M | 314.00M | 283.00M | 286.60M | 281.10M | 254.00M | 256.70M | 264.60M | 237.88M | 197.40M | 176.12M | 168.73M | 153.90M | 131.39M | 147.73M | 134.30M | 90.80M | 68.80M | 76.40M | 99.10M |
| EBITDA | 1.73B | 1.82B | 3.16B | 2.41B | 1.59B | 1.40B | 1.45B | 1.48B | 1.56B | 1.30B | 1.79B | 1.52B | 1.30B | 1.59B | 1.63B | 1.50B | 1.33B | 1.33B | 1.18B | 1.05B | 950.36M | 723.84M | 559.12M | 452.11M | 242.80M | 163.10M | 151.10M | -502.19M |
| EBITDA Ratio | 18.72% | 18.31% | 29.27% | 25.52% | 20.45% | 18.67% | 18.82% | 18.10% | 20.82% | 17.85% | 18.42% | 20.58% | 17.38% | 21.43% | 22.12% | 21.25% | 19.88% | 21.27% | 21.20% | 21.07% | 19.99% | 17.17% | 15.37% | 13.32% | 14.46% | 11.66% | 13.34% | -31.07% |
| Operating Income | 1.26B | 1.43B | 2.38B | 1.97B | 1.23B | 1.10B | 1.17B | 1.28B | 1.40B | 983.00M | 1.48B | 1.20B | 995.00M | 1.30B | 1.36B | 1.22B | 1.09B | 1.13B | 968.11M | 901.44M | 795.43M | 592.45M | 411.39M | 317.82M | 152.00M | 94.30M | 74.70M | -601.28M |
| Operating Income Ratio | 13.64% | 14.45% | 22.07% | 20.89% | 15.93% | 14.62% | 15.11% | 16.99% | 18.67% | 13.22% | 20.64% | 16.27% | 13.25% | 17.58% | 18.23% | 16.86% | 16.28% | 17.99% | 17.59% | 17.58% | 16.79% | 14.42% | 11.34% | 9.29% | 6.89% | 6.47% | 4.89% | -37.20% |
| Total Other Income/Expenses | -132.00M | -193.00M | 218.00M | -87.00M | -155.00M | -175.00M | -135.00M | -142.00M | -101.00M | -134.00M | 192.00M | -133.00M | -130.77M | -99.28M | -131.18M | -203.42M | -178.93M | -94.73M | -57.66M | -76.55M | -58.66M | -50.07M | -114.80M | -116.84M | -137.60M | -40.40M | -93.80M | -74.92M |
| Income Before Tax | 1.13B | 1.24B | 2.60B | 1.88B | 1.08B | 926.00M | 1.03B | 1.09B | 1.10B | 849.00M | 1.35B | 1.07B | 856.30M | 1.18B | 1.23B | 1.02B | 912.40M | 1.03B | 910.45M | 835.13M | 737.80M | 542.38M | 332.60M | 200.98M | 14.40M | 53.90M | -19.10M | -676.20M |
| Income Before Tax Ratio | 12.21% | 12.50% | 24.09% | 19.96% | 13.93% | 12.30% | 13.36% | 14.45% | 14.72% | 11.42% | 18.86% | 14.47% | 11.40% | 16.07% | 16.47% | 14.06% | 13.61% | 16.48% | 16.54% | 16.29% | 15.57% | 13.20% | 9.17% | 5.87% | 0.65% | 3.70% | -1.25% | -41.84% |
| Income Tax Expense | 248.00M | 264.00M | 597.00M | 460.00M | 247.00M | 182.00M | 241.00M | 429.00M | 373.00M | 262.00M | 500.00M | 401.90M | 349.00M | 425.50M | 460.40M | 386.80M | 358.57M | 407.58M | 364.18M | 335.93M | 301.08M | 220.22M | 148.69M | 96.03M | 15.70M | 27.00M | 3.20M | -50.24M |
| Net Income | 854.00M | 946.00M | 2.00B | 1.43B | 858.00M | 736.00M | 772.00M | 645.00M | 709.00M | 556.00M | 849.00M | 555.70M | 470.60M | 720.90M | 729.10M | 581.50M | 339.94M | 586.42M | 546.28M | 499.20M | 436.72M | 322.15M | 162.30M | 102.05M | -3.40M | 26.90M | -22.30M | -625.96M |
| Net Income Ratio | 9.23% | 9.57% | 18.49% | 15.16% | 11.11% | 9.77% | 10.01% | 8.58% | 9.46% | 7.48% | 11.88% | 7.53% | 6.27% | 9.78% | 9.78% | 8.02% | 5.07% | 9.35% | 9.93% | 9.74% | 9.22% | 7.84% | 4.47% | 2.98% | -0.15% | 1.84% | -1.46% | -38.73% |
| EPS | 7.59 | 8.12 | 15.90 | 10.68 | 6.38 | 5.41 | 5.63 | 4.58 | 4.92 | 3.83 | 5.58 | 3.49 | 2.95 | 4.08 | 3.91 | 2.99 | 1.76 | 2.98 | 2.71 | 2.45 | 2.11 | 1.67 | 0.87 | 0.57 | -0.03 | 0.23 | -0.19 | -5.33 |
| EPS Diluted | 7.52 | 7.98 | 15.53 | 10.52 | 6.29 | 5.29 | 5.50 | 4.51 | 4.87 | 3.81 | 5.54 | 3.46 | 2.92 | 4.05 | 3.87 | 2.97 | 1.74 | 2.94 | 2.66 | 2.35 | 2.02 | 1.62 | 0.83 | 0.54 | -0.03 | 0.22 | -0.19 | -5.33 |
| Weighted Avg Shares Out | 112.00M | 116.00M | 125.00M | 134.00M | 134.00M | 136.00M | 137.00M | 140.00M | 144.00M | 145.00M | 152.00M | 158.60M | 158.70M | 175.70M | 185.90M | 194.30M | 193.24M | 196.99M | 201.83M | 203.75M | 206.97M | 192.91M | 186.56M | 179.04M | 136.00M | 119.56M | 115.84M | 117.45M |
| Weighted Avg Shares Out (Dil) | 113.00M | 118.00M | 128.00M | 136.00M | 136.00M | 139.00M | 140.00M | 142.00M | 145.00M | 145.00M | 153.00M | 160.10M | 160.20M | 177.30M | 187.80M | 196.00M | 195.26M | 199.54M | 205.53M | 212.42M | 216.20M | 199.48M | 195.55M | 188.99M | 136.00M | 120.90M | 116.15M | 117.45M |
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Quest Diagnostics to Speak at the Morgan Stanley 22nd Annual Global Healthcare Conference
SECAUCUS, N.J. , Aug. 28, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and...
Quest Diagnostics Expands in North America With New Acquisition
DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.
Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio
Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.
Quest Diagnostics Completes Acquisition of LifeLabs, Enhancing Access to Diagnostic Innovation
SECAUCUS, N.J. and TORONTO , Aug. 26, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its acquisition of LifeLabs from OMERS.
Quest Diagnostics (DGX) Up 6.3% Since Last Earnings Report: Can It Continue?
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics to Acquire University Hospitals' Outreach Laboratory Services Business
Transaction to broaden access to innovative, quality diagnostic information services powering affordable care in Ohio SECAUCUS, N.J., and CLEVELAND , Aug. 21, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, and University Hospitals, one of...
Quest Diagnostics (DGX) Debuts Micronutrient Deficiency Panels
Quest Diagnostics (DGX) introduces 13 blood tests to identify micronutrient deficiencies.
Quest Diagnostics Prices $1.85 Billion of Senior Notes
SECAUCUS, N.J. , Aug. 15, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering of $400 million aggregate principal amount of its 4.600% senior notes...
Source: https://incomestatements.info
Category: Stock Reports